David B. Clifford mainly focuses on Internal medicine, Immunology, Progressive multifocal leukoencephalopathy, Viral load and JC virus. His Internal medicine research is multidisciplinary, incorporating perspectives in Peripheral neuropathy, Efavirenz and Oncology. His Immunology study integrates concerns from other disciplines, such as Gastroenterology and Cerebrospinal fluid.
The Viral load study combines topics in areas such as Neuropathic pain, HIV-associated neurocognitive disorder, Regimen, Hepatitis C and Neurocognitive. His Neurocognitive research includes elements of Acquired immunodeficiency syndrome and Depression. His research integrates issues of Disease and Pathology in his study of JC virus.
Internal medicine, Immunology, Progressive multifocal leukoencephalopathy, Neurocognitive and Acquired immunodeficiency syndrome are his primary areas of study. His biological study spans a wide range of topics, including Gastroenterology, Peripheral neuropathy, Viral load and Oncology. As a part of the same scientific study, David B. Clifford usually deals with the Immunology, concentrating on Cerebrospinal fluid and frequently concerns with Pharmacology.
His study in Progressive multifocal leukoencephalopathy is interdisciplinary in nature, drawing from both Natalizumab, Leukoencephalopathy, Disease and Pathology. His research investigates the connection between Neurocognitive and topics such as HIV-associated neurocognitive disorder that intersect with problems in Cognitive disorder. His Acquired immunodeficiency syndrome research is multidisciplinary, incorporating perspectives in Randomized controlled trial and Pediatrics.
His primary scientific interests are in Internal medicine, Disease, Neurocognitive, Immunology and Progressive multifocal leukoencephalopathy. His studies in Internal medicine integrate themes in fields like Gastroenterology, Viral load, Oncology and Coinfection. His Disease study integrates concerns from other disciplines, such as Pathogenesis, Sarcoidosis, Neurosarcoidosis, Intensive care medicine and Clinical endpoint.
His Neurocognitive research is multidisciplinary, incorporating elements of Cross-sectional study, Confounding, Dementia and HIV-associated neurocognitive disorder. In his work, RNA and Optimal treatment is strongly intertwined with Antiretroviral therapy, which is a subfield of Immunology. His Progressive multifocal leukoencephalopathy research integrates issues from Natalizumab and Cancer research.
David B. Clifford focuses on Immunology, Neurocognitive, Internal medicine, Disease and HIV-associated neurocognitive disorder. His Immunology study combines topics from a wide range of disciplines, such as Cerebrospinal fluid and Cohort. David B. Clifford combines subjects such as Psychosocial, Acquired immunodeficiency syndrome, Asymptomatic, Dementia and Neurology with his study of Neurocognitive.
His studies deal with areas such as JC virus and Progressive multifocal leukoencephalopathy as well as Neurology. His Internal medicine study incorporates themes from Gastroenterology, White matter, Oncology and Coinfection. His work carried out in the field of HIV-associated neurocognitive disorder brings together such families of science as Single-nucleotide polymorphism and Cognition.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated research nosology for HIV-associated neurocognitive disorders
A. Antinori;G. Arendt;J. T. Becker;B. J. Brew.
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
R. K. Heaton;D. B. Clifford;D. R. Franklin;S. P. Woods.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
Robert K. Heaton;Donald R. Franklin;Ronald J. Ellis;J. Allen McCutchan.
Journal of NeuroVirology (2011)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
Tarek A. Yousry;Eugene O. Major;Caroline Ryschkewitsch;Gary Fahle.
The New England Journal of Medicine (2006)
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
Scott Letendre;Jennifer Marquie-Beck;Edmund Capparelli;Brookie Best.
JAMA Neurology (2008)
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
David W Haas;Heather J Ribaudo;Richard B Kim;Camlin Tierney.
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B Clifford;Andrea DeLuca;David M Simpson;Gabriele Arendt.
Lancet Neurology (2010)
PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section
Joseph R. Berger;Allen J. Aksamit;David B. Clifford;Larry Davis.
HIV and aging: State of knowledge and areas of critical need for research. a report to the NIH office of AIDS research by the HIV and aging working group
Kevin P. High;Mark Brennan-Ing;David B. Clifford;Mardge H. Cohen.
Journal of Acquired Immune Deficiency Syndromes (2012)
HIV-associated neurocognitive disorder
David B Clifford;Beau M Ances.
Lancet Infectious Diseases (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: